08:04 AM EDT, 07/02/2025 (MT Newswires) -- Organon & Co. ( OGN ) said Wednesday its phase 2 study of OG-6219 in patients with endometriosis-related pain did not meet its primary endpoint and that it will discontinue development of the drug candidate.
In the trial, OG-6219 failed to demonstrate improvement in patients with moderate-to-severe pelvic pain compared with placebo, the company said.
Shares of Organon were down 2.8% in premarket trading.